Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept Dose Reduction in Ankylosing Spondylitis
NCT02638896Phase 4Unknown
- Start
- Jan 2016
- Primary completion
- Feb 2017
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 4 trial of etanercept in ankylosing spondylitis (AS). Status: unknown.
02
Drugs
etanercept
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02638896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02638896.